|Q&A: Timothy Mayleben, CEO of Aastrom Biosciences|
|By Staff and Wire Reports|
|Monday, 09 April 2012 08:50|
Last month, Aastrom Biosciences, announced that it had completed an impressive, $40 million private placement financing. The development was noted as a particularly bullish sign for emerging biotechs everywhere.
His firm, Aastrom Biosciences, is one of the most exciting regenerative medicine companies in the healthcare sector. They are engaged in the development of autologous cell products for treatment of severe, chronic cardiovascular diseases. Their proprietary cell-processing technology enables the manufacture of ixmyelocel-T, a patient-specific multicellular therapy expanded from a patient's own bone marrow and delivered directly to damaged tissues. The cellular therapy resulting from this process contains expanded populations of mixed stem and progenitor cells to support the regeneration of cardiovascular tissue. The company's cell manufacturing process works exclusively with adult stem cells derived from and administered to the same patient. This approach reduces the risk of rejection and increases the likelihood of integration with the surrounding tissues, eliminating the need for immunosuppressive drugs.
His exclusive interview with BioMedReports appears below: